Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2

Sponsor Class

OTHER 24INDUSTRY 16UNKNOWN 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 2

Interventions

S 1 (combination) 12Capecitabine 11Paclitaxel 9Cisplatin 9apatinib 8Oxaliplatin 8pyrotinib 6nimotuzumab 6130-nm albumin-bound paclitaxel 6titanium silicide 5sintilimab 5camrelizumab 5anlotinib 5Etoposide 5Docetaxel 5Carboplatin 5Trastuzumab 4Radiotherapy, Intensity-Modulated 4Irinotecan 4Bevacizumab 4Albumin-Bound Paclitaxel 4nedaplatin 3Vinorelbine 3Temozolomide 3Tegafur 3Taxes 3Radiosurgery 3Gemcitabine 3Fluorouracil 3Epirubicin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × UNKNOWN × icotinib × Clear all
NCT02960607 2016-11-18

High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC

ChineseAMS

Phase 2 Unknown
25 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02961270 2016-11-11

Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutation

ChineseAMS

Phase 2 Unknown
30 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡